The FDA’s Oncologic Drugs Advisory Committee is scheduled to review Johnson & Johnson (JNJ) and Legend Biotech Corp's (LEGN) Carvykti on March 15, 2024, for an expanded indication.The proposed expanded indication is for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least one prior line of therapy.Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, is already approved for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy.The drug pulled in $500 million in global sales in full-year 2023 compared to $133 million in 2022.JNJ closed Tuesday's (Feb.27, 2024) trading at $160.98, up 0.12%.